Eledon Pharmaceuticals, Inc. (ELDN)

Market Cap	33.24M
Revenue (ttm)	n/a
Net Income (ttm)	-38.39M
Shares Out	13.76M
EPS (ttm)	-2.67
PE Ratio	n/a
Forward PE	2.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,713
Open	2.45
Previous Close	2.37
Day's Range	2.36 - 2.68
52-Week Range	1.90 - 4.14
Beta	2.04
Analysts	Buy
Price Target	18.56 (+668.21%)
Earnings Date	May 10, 2023

About ELDN

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the trea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: ELDN

Analyst Forecast

According to 11 analysts, the average rating for ELDN stock is "Buy." The 12-month stock price forecast is $18.56, which is an increase of 668.21% from the latest price.

Price Target

$18.56

(668.21% upside)

Analyst Consensus: Buy